OncoMatch/Clinical Trials/NCT06429150
Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma
Is NCT06429150 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies CAR-T cells for multiple myeloma.
Treatment: CAR-T cells — The aim of this clinical trial is to assess the feasibility, safety, and efficacy of CAR-T cell therapy targeting multiple cancer cell antigens in high-risk multiple myeloma or plasmacytoma as part of a frontline treatment regimen for patients. Another goal of the study is to learn more about the persistence and function of these CAR-T cells in the body.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Prior therapy
Must have received: autologous stem cell transplant
After prior auto-SCT is eligible regardless of other prior therapies
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify